| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/28/2005 | WO2005037995A2 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy |
| 04/28/2005 | WO2005037949A2 Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine |
| 04/28/2005 | WO2005037928A2 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | WO2005037862A1 Targeting compositions and preparation thereof |
| 04/28/2005 | WO2005037711A1 Amphiphilic [5:1]- and [3:3]- hexakisadducts of fullerenes |
| 04/28/2005 | WO2005037336A1 Hydrogel-containing medical articles and methods of using and making the same |
| 04/28/2005 | WO2005037325A1 X-ray contrast medium containing liposome and method for preparation thereof |
| 04/28/2005 | WO2005037320A2 Process for preparing polysaccharide-protein conjugate vaccines |
| 04/28/2005 | WO2005037319A1 Composition for tablet rapidly disintegrable in mouth |
| 04/28/2005 | WO2005037306A1 Combination therapy |
| 04/28/2005 | WO2005037297A1 Compositions and methods for inhibiting cell senescence and hyperproliferative disorders |
| 04/28/2005 | WO2005037296A1 Anti-coronavirus agent |
| 04/28/2005 | WO2005037294A1 Compositions for controlling parasites comprising a combination of abamectin and ivermectin |
| 04/28/2005 | WO2005037267A1 Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method |
| 04/28/2005 | WO2005037266A1 Pharmaceutical composition comprising 5-methyl-2-(2’-chloro-6’-fluoroanilino)phenylacetic acid |
| 04/28/2005 | WO2005037265A1 Concurrent drugs |
| 04/28/2005 | WO2005037264A1 Jelly preparation containing biguanide medicine |
| 04/28/2005 | WO2005037254A1 Tablet quickly disintegrating in oral cavity |
| 04/28/2005 | WO2005037251A1 Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds |
| 04/28/2005 | WO2005037248A1 Glycoprotein and/or glycomacropeptide containing preparations for medical uses |
| 04/28/2005 | WO2005037247A2 Oral matrix formulations of doxazosin |
| 04/28/2005 | WO2005037245A2 A multiple route medication for the treatment of rhinitis and asthma |
| 04/28/2005 | WO2005037157A1 Enhancing transdermal administration of hydrophilic drugs |
| 04/28/2005 | WO2005013955A3 Topical composition comprising terbinafine and hydrocortisone |
| 04/28/2005 | WO2005001023A3 Method and carrier complexes for delivering molecules to cells |
| 04/28/2005 | WO2004110390A3 Anti-cd74 immunoconjugates and methods |
| 04/28/2005 | WO2004104020A3 Repeat sequence protein polymer active agent conjugates, methods and uses |
| 04/28/2005 | WO2004103342A3 Injectable sustained release compositions |
| 04/28/2005 | WO2004093848A3 Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| 04/28/2005 | WO2004075822A8 Pharmaceutical composition for transdermal or transmucosal administration |
| 04/28/2005 | WO2004060396A3 Immunogenic compositions containing phospholpid |
| 04/28/2005 | WO2004060378A8 Compositions comprising particles containing alumina with compounds bound to the alumina surface, delivery systems and methods of preparation thereof |
| 04/28/2005 | WO2004049907A3 Compositions and methods for treating transplants |
| 04/28/2005 | WO2004032963A9 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 04/28/2005 | WO2003101425A8 Therapeutic agent-containing polymeric nanoarticles |
| 04/28/2005 | WO2003099201A3 Compositions and methods of use for a fibroblast growth factor |
| 04/28/2005 | WO2003087389A3 Biologic modulations with nanoparticles |
| 04/28/2005 | WO2003086283A9 Metastasis modulating activity of highly sulfated oligosaccharides |
| 04/28/2005 | US20050090650 purifying polymer by ion exchange chromatography to obtain a purified polymer |
| 04/28/2005 | US20050090641 miniblock polymers that can self-assemble into three-dimensional materials through liquid crystalline behavior |
| 04/28/2005 | US20050090537 Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof |
| 04/28/2005 | US20050090481 having improved stability and side effect reduction; tissue-targeted therapy |
| 04/28/2005 | US20050090451 Treatment of cancer with glutamine |
| 04/28/2005 | US20050090447 Peptides that promote complement activation |
| 04/28/2005 | US20050090445 Truncated keratinocyte growth factor (KGF) having increased biological activity |
| 04/28/2005 | US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models: |
| 04/28/2005 | US20050089970 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 04/28/2005 | US20050089592 Nut skin products |
| 04/28/2005 | US20050089581 Applying a therapeutically effective amount of a magnesium-containing composition to the individual's skin, the magnesium-containing composition comprising about 25 to 35 weight percent magnesium chloride, a solvent, a gelling agent and glycerin |
| 04/28/2005 | US20050089578 Methods and devices for tissue repair |
| 04/28/2005 | US20050089577 In which medicine can be easily solubilized, dispersed or suspended and which can be easily swallowed because of being liquid, has favorable working properties in sterilization and so on and a high stability, also exhibits an effect of masking bitterness |
| 04/28/2005 | US20050089576 For therapy of gastroenterological conditions and/or diseases, such as Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis |
| 04/28/2005 | US20050089575 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 04/28/2005 | US20050089574 Overcoating drug; sustained release; cardiovascular disorders; mixture of acrylic polymer and vinyl acetate polymer |
| 04/28/2005 | US20050089573 Oral pharmaceutical formulation containing ibandronate |
| 04/28/2005 | US20050089571 Pharmaceutical formulation for the active ingredient budesonide |
| 04/28/2005 | US20050089569 erodible matrix comprising drugs, coatings comprising cellulose derivatives which is insoluble in aqueous medium and a second cellulose derivative which is water soluble, plasticizers and fillers, for drug delivery into an aqueous medium by erosion at controlled rates; time-release agents |
| 04/28/2005 | US20050089568 Melt-extruded orally administrable opioid formulations |
| 04/28/2005 | US20050089567 Popping oral pharmaceutical compositions |
| 04/28/2005 | US20050089565 Methylcellulose and, as separate ingredients, a disintegrating agent, a binder, and a diluent; laxative for treating constipation |
| 04/28/2005 | US20050089564 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089563 Rapidly disintegrating methylcellulose tablets |
| 04/28/2005 | US20050089562 First phase of a compacted mixture of methylcellulose with a viscosity greater than 1000 centipoise and an edible calcium salt, blended with a second phase that may contain a disintegrating agent, a wetting agent, a lubricant and/or a second diluent |
| 04/28/2005 | US20050089561 Blending granulated methylcellulose and granulated diluent to form an intragranulated tablet; use treating constipation |
| 04/28/2005 | US20050089560 With a diluent and a crosprovidone; treating constipation |
| 04/28/2005 | US20050089557 Tablets having improved tabletting characteristics and process for producing the same |
| 04/28/2005 | US20050089556 Composition for treating hemorrhoids |
| 04/28/2005 | US20050089555 Administering phospholipid, bile acid and water; treating adipose tissue disorders such as cellulite, tumors e.g. lipomas |
| 04/28/2005 | US20050089554 Apparatus and method for enhancing transdermal drug delivery |
| 04/28/2005 | US20050089548 Hydrocolloid film-forming material and microparticles containing active agent that rapidly disintegrates in the mouth to release the active agent such as flavorants, drugs, nutraceuticals, fragrances, food acids |
| 04/28/2005 | US20050089547 Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
| 04/28/2005 | US20050089539 Antimicrobial compositions and methods |
| 04/28/2005 | US20050089538 Carcinoembryonic antigen (CEA); administering a humanized Class III, anti-CEA, monoclonal antibody to treat cancer; complementarity-determining regions (CDR) of given amino acid sequences; diagnostic and therapeutic conjugates; transformed cells |
| 04/28/2005 | US20050089536 Use of comb copolymers based on acryloyldimethyltaurine acid in cosmetic, pharmaceutical and dermatological products |
| 04/28/2005 | US20050089535 Delivery of biologically active agents |
| 04/28/2005 | US20050089526 Monomeric unit of the complex containin HIV-1 gp120 and HIV-1 gp41, (ii) the gp4l has one or more mutations in its N-terminal helix, and (iii) the gp120 and gp41 are bound to each other by a disulfide bond between a cysteine residue introduced into the gp120 and a cysteine residue introduced into gp41 |
| 04/28/2005 | US20050089524 Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
| 04/28/2005 | US20050089523 Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids |
| 04/28/2005 | US20050089518 Prospective identification and characterization of breast cancer stem cells |
| 04/28/2005 | US20050089506 Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| 04/28/2005 | US20050089504 Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules |
| 04/28/2005 | US20050089503 Cationic polymers having degradable crosslinks |
| 04/28/2005 | US20050089497 Mixture of 2-methylpropanediol/1,3/ monoester, surfactant, oil and water |
| 04/28/2005 | US20050089495 Transdermal transport of compounds |
| 04/28/2005 | US20050089493 Spermine peptide surfactants with amide or amine bonds for surfactants used to transfer cells |
| 04/28/2005 | US20050089480 Active polypeptides for nasal sprays with polysaccharides like dextran |
| 04/28/2005 | US20050089479 Delivery of sedative-hypnotics through an inhalation route |
| 04/28/2005 | US20050089478 Formeratol and budesonide for treatment of respiratory system disorders such as chronc obstructive pulmonary disease |
| 04/28/2005 | US20050089477 Medicaments |
| 04/28/2005 | US20050089476 Dissolving the active ingredient in a minimal quantity of an alcoholic solvent, sterilizing filtration, sonication |
| 04/28/2005 | US20050087719 Magnetic nanodispersion with cyclodextrines and method for the production thereof |
| 04/28/2005 | CA2576040A1 Hydrogel-containing medical articles and methods of using and making the same |
| 04/28/2005 | CA2542755A1 Biguanide drug-containing jelly preparation |
| 04/28/2005 | CA2542753A1 Enhancing transdermal administration of hydrophilic drugs |
| 04/28/2005 | CA2542694A1 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | CA2542684A1 Targeting compositions and preparation thereof |
| 04/28/2005 | CA2542662A1 Pharmaceutical combinations comprising il-21 |
| 04/28/2005 | CA2542427A1 Viral fibers |
| 04/28/2005 | CA2542128A1 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 04/28/2005 | CA2541265A1 Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |